After $600 Million Typo, Valeant CEO Is Back on the Hot Seat

By
Doni Bloomfield
,
Cordell Eddings
, and
Cynthia Koons
  • Conference call gets baffled, angry reaction from investors
  • Shares plunge the most ever as analysts question company chief

Valeant Suffers Biggest Drop on Record, What's Next?

Michael Pearson and his company, Valeant Pharmaceuticals International Inc., were supposed to calm Wall Street doubters on Tuesday. Instead: chaos.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.

Read this article on the Terminal Request a demo to learn more

You might like:
  1. New Trump Move Restricts or Bans Travel From Eight Countries
  2. This Startup Is Luring Top Talent With $3 Million Pay Packages
  3. IPhone Disappointment Hammers Suppliers, Fuels Taiwan Outflows
  4. Storm Watches Issued for North Carolina as Maria Churns North
  5. A L'Oreal Heiress Is Now the World's Richest Woman